PD-1/PD-L1-IN-23

Cat. No.:	HY-145774
CAS No.:	2597056-04-5
Molecular Formula:	$C_{32}H_{30}BrCl_2N_3O_6$
Molecular Weight:	703.41
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (355.41 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.4216 mL	7.1082 mL	14.2165 mL
	5 mM	0.2843 mL	1.4216 mL	2.8433 mL
	10 mM	0.1422 mL	0.7108 mL	1.4216 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (2.96 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (2.96 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester prodrug of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice[1].

IC_{50} & Target

PD-1/PD-L1[1]

REFERENCES

[1]. Liu L, et al. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity. J Med Chem. 2021;64(12):8391-8409.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA